// App-Quantinova.ai

2626 : Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease

Researchers

Presenter

  • Matthew M. Heeney

Principal Investigators

  • David C. Rees

  • Mariane de Montalembert

  • Isaac Odame

  • R. Clark Brown

  • Yasser Wali

  • Thu Thuy Nguyen

  • Du Lam

  • Raquel Merino Herranz

  • Julie Kanter

Medical Centers

  • Dana Farber Boston Childrens Cancer and Blood Disorder Center, Harvard Medical School, Boston, MA

  • Department of Oncology, King's College Hospital, London, United Kingdom

  • AP-HP Hopital Universitaire Necker Enfants Malades, Paris, France

  • The Hospital for Sick Children (SickKids), Toronto, ON, Canada

  • Children's Healthcare of Atlanta, Atlanta, GA

  • Sultan Qaboos University Hospital, Muscat, Oman

  • Novartis Pharma S.A.S., Rueil-Malmaison, France

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Pharmaceuticals AG, Basel, Switzerland

  • Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL

Locations

  • United Kingdom

  • France

  • Canada

  • United States

  • Oman

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Acute chest syndrome

  • Sickle cell anemia

  • Dactylitis

Biomarkers

  • Stearoyl-CoA desaturase

  • Volatile organic compounds

Drug/Treatment

  • Erythropoietin

  • SelG1

  • Proglumide

  • Hydroxyurea

  • Hydroxycarbamide

  • Glutamine

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03474965

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved